J M Vierling
Overview
Explore the profile of J M Vierling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
597
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liberal R, de Boer Y, Andrade R, Bouma G, Dalekos G, Floreani A, et al.
Aliment Pharmacol Ther
. 2016 Dec;
45(5):723-732.
PMID: 28004405
Background: High-quality data on the management of autoimmune hepatitis (AIH) are scarce. Despite published guidelines, management of AIH is still expert based rather than evidence based. Aim: To survey expert...
2.
Landis C, Ghabril M, Rustgi V, Di Bisceglie A, Maliakkal B, Rockey D, et al.
Dig Dis Sci
. 2016 Jan;
61(6):1728-34.
PMID: 26781427
Background: Overt hepatic encephalopathy (OHE) is a frequent complication of decompensated cirrhosis. Aims: A multicenter prospective observational study was performed to assess the most commonly recorded presenting manifestations of OHE...
3.
Lagging M, Brown A, Mantry P, Ramji A, Weilert F, Vierling J, et al.
J Viral Hepat
. 2015 Sep;
23(2):80-8.
PMID: 26353843
Unlabelled: Grazoprevir (MK-5172, Merck & Co., Inc.) is a selective inhibitor of the hepatitis C virus (HCV) NS3/4a protease. The aim of this study was to evaluate the safety and...
4.
Zeuzem S, Flisiak R, Vierling J, Mazur W, Mazzella G, Thongsawat S, et al.
Aliment Pharmacol Ther
. 2015 Aug;
42(7):829-44.
PMID: 26238707
Background: Alisporivir (ALV) is an oral, host-targeting agent with pangenotypic anti-hepatitis C virus (HCV) activity and a high barrier to resistance. Aim: To evaluate efficacy and safety of ALV plus...
5.
Mokhtarani M, Diaz G, Rhead W, Berry S, Lichter-Konecki U, Feigenbaum A, et al.
Mol Genet Metab
. 2013 Oct;
110(4):446-53.
PMID: 24144944
Background: Phenylacetic acid (PAA) is the active moiety in sodium phenylbutyrate (NaPBA) and glycerol phenylbutyrate (GPB, HPN-100). Both are approved for treatment of urea cycle disorders (UCDs) - rare genetic...
6.
Barshes N, Horwitz I, Franzini L, Vierling J, Goss J
Am J Transplant
. 2007 Mar;
7(5):1265-70.
PMID: 17359503
Extended criteria donor (ECD) liver allografts are often allocated to less severely ill liver transplant (LT) candidates who are at a relatively lower risk of pretransplant mortality, but it is...
7.
Firpi R, Tran T, Flores P, Nissen N, Colquhoun S, Shackleton C, et al.
Aliment Pharmacol Ther
. 2004 Apr;
19(9):1033-9.
PMID: 15113371
Background: Sirolimus is a potent immunosuppressive medication that acts by inhibiting T-cell proliferation. It has been used in kidney transplantation because of its lack of nephrotoxicity. It is now being...
8.
Amankonah T, Strom C, Vierling J, Petrovic L
Am J Gastroenterol
. 2001 Aug;
96(8):2520-2.
PMID: 11513216
No abstract available.
9.
Vierling J
Best Pract Res Clin Gastroenterol
. 2001 Aug;
15(4):591-610.
PMID: 11492970
Since the aetiopathogenesis of primary sclerosing cholangitis (PSC) in humans remains undefined, investigators have studied a variety of animal models to gain insights into immunopathogenetic mechanisms associated with obliterative fibrous...
10.
Yu A, Vierling J, Colquhoun S, Arnaout W, Chan C, Khanafshar E, et al.
Liver Transpl
. 2001 Jul;
7(6):513-7.
PMID: 11443579
Donor shortage has led to the use of hepatitis B core antibody (anti-HBc)--positive (anti-HBc(+)) liver allografts for patients in need of relatively urgent orthotopic liver transplantation (OLT). Because anti-HBc(+) allografts...